SCHEMBL3148729

SCHEMBL3148729

COc1ccc(N2CCN(CCCO)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.73
DRD2 P14416 4/20 0.69
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
HTR2A P28223 2/20 0.61
DRD4 P21917 1/20 0.60
HTR1A P08908 5/20 0.59
HTR7 P34969 2/20 0.59
ADRA1A P35348 1/20 0.59
KCNH2 Q12809 1/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
SOD1 P00441 1/20 0.55
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9559845 0.90 DRD2 (0.73) HSD17B10DRD2MEN1KMT2AHTR2A
Hydrochloric Acid SCHEMBL11447131 0.89 DRD2 (0.71) HSD17B10DRD2MEN1KMT2AHTR2A
SCHEMBL18937451 0.86 DRD2 (0.82) HSD17B10DRD2MEN1KMT2AHTR2A
SCHEMBL16303868 0.84 DRD2 (0.79) HSD17B10DRD2MEN1KMT2AHTR2A
SCHEMBL11354876 0.84 HSD17B10 (1.00) HSD17B10DRD2MEN1KMT2AHTR2A
SCHEMBL10994325 0.84 HSD17B10 (0.73) HSD17B10DRD2MEN1KMT2AHTR2A
Hydrochloric Acid SCHEMBL11209809 0.84 DRD2 (0.79) HSD17B10DRD2MEN1KMT2AHTR2A
Hydrochloric Acid SCHEMBL11639840 0.84 HSD17B10 (0.73) HSD17B10DRD2MEN1KMT2AHTR2A
SCHEMBL11404382 0.84 KCNH2 (0.81) DRD2HTR2ADRD4HTR1AHTR7
SCHEMBL3186225 0.83 HSD17B10 (0.91) HSD17B10DRD2MEN1KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247420-B2 Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents REVIVA PHARMACEUTICALS, INC. (US) 2012-08-21 US disclosed
EP-2162135-A1 COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS Reviva Pharmaceuticals, Inc. (US) 2010-03-17 EP disclosed
WO-2008144764-A1 COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS REVIVA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed
US-20080293736-A1 Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents REVIVA PHARMACEUTICALS, INC. (US) 2008-11-27 US disclosed
US-5246935-A Cardiovascular and gastrointestinal NOVO NORDISK A/S (DK) 1993-09-21 US disclosed
EP-0544765-A1 PIPERAZINYL DERIVATIVES. NOVO NORDISK AS (DK) 1993-06-09 EP disclosed
WO-1992003426-A1 PIPERAZINYL DERIVATIVES NOVO NORDISK A/S (DK) 1992-03-05 WO disclosed
US-4250310-A ANTIARRHYTHMIA AND VASODILATION AGENTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1981-02-10 US disclosed
US-4140790-A ANTIARRHYTHMIA, CORONARY DILATORS RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1979-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293736-A1 Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents GRIN2D, GRIN2C, AP3D1 HSD17B10 1029/4885DRD2 26/4885MEN1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.